High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6622-6630

  Boo, Lee Ming ^a   Lin, H Helen ^a   Chung, Vincent ^d   Zhou, Bingsen ^d   Louie, Stan G ^a   O'Reilly, Michael A ^e   Yen, Yun ^a,d   Ann, David K ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CISPLATIN; DOUBLE STRANDED DNA; DOXORUBICIN; GYRASE INHIBITOR; HIGH MOBILITY GROUP A2 PROTEIN; HISTONE H2A; IRINOTECAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL TYPE; CHEMOSENSITIVITY; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; GENE EXPRESSION; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METAPHASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION; X IRRADIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL DIVISION; DNA DAMAGE; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOXORUBICIN; ENZYME ACTIVATION; HELA CELLS; HISTONES; HMGA2 PROTEIN; HUMANS; INTERPHASE; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 23044448902     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0086     Document Type: Article

References (59)

1. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001;277:63-81.
2. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmental regulated factor HMGI-C. Nature 1995; 376:771-4.
3. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998; 23:350-7.
4. Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519:13-29.
5. Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 2003;89:2104-9.
6. Finelli P, Pierantoni GM, Giardino D, et al. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res 2002;62:2398-405.
7. Masciullo V, Baldassarre G, Pentimalli F, et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 2003;24:1191-8.
8. Berlingieri MT, Manfioletti G, Santoro M, et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545-53.
9. Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8.
10. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64:2024-9.
11. Langelotz C, Schmid P, Jakob C, et al. Expression of high-mobiliry-group- protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003;88:1406-10.
12. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
13. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004;3:889-900.
14. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-31.
15. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
16. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002; 297:547-51.
17. Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:909-18.
18. Pilch DR, Sedelnikova OA, Redon C, et al. Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003;81:123-9.
19. Burma S, Chen BR, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
20. Rogalcou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273: 5858-68.
21. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001;276:47759-62.
22. Zimmerman ES, Chen J, Andersen JL, et al. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and γ-H2AX focus formation. Mol Cell Biol 2004;24: 9286-94.
23. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
24. Li D, Lin HH, McMahon M, Ma H, Ann DK. Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. J Biol Chem 1997;272:25062-70.
25. Li S, Ting NS, Zheng L, et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 2000;406:210-5.
26. Lees-Miller SP, Godbout R, Chan DW, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995;267:1183-5.
27. Nghiem P, Park PK, Kim Y-S, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002;277:4428-34.
28. Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003;23: 9104-16.
29. 2-M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 2004;166:517-26.
30. Zhou BB, Chaturvedi P, Spring K, et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 2000;275:10342-8.
31. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59: 4375-82.
32. Hall-Jackson CA, Cross DA, Morrice N, Smythe C. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 1999;18:6707-13.
33. Willmore E, de Caux S, Sunter NJ, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase 11 poisons used in the treatment of leukemia. Blood 2004;103: 4659-65.
34. Cortez D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 2003;278:37139-45.
35. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-15.
36. Hannon GJ. RNA interference. Nature 2002;418: 244-51.
37. Kim DH, Longo M, Han Y, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004;22:321-5.
38. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
39. Sledz CA, Williams BR. RNA interference and double-stranded-RNA-activated pathways. Biochem Soc Trans 2004;32:952-6.
40. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70.
41. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand crosslinks in mammalian cells. Mol Cell Biol 2000;20:7980-90.
42. Zhou X, Bertson KF, Przybysz K, et al. Gertomic structure and expression of the murine Hmgi-c gene. Nucleic Acids Res 1996;24:4071-7.
43. Anand A, Chada K. In vim modulation of Hmgic reduces obesity. Nat Genet 2000;24:377-80.
44. Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6:237-46.
45. Rogalla P, Drechsler K, Kazmierczak B, et al. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 1997;19: 153-6.
46. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science 2002;298:1435-8.
47. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 2003;421:961-6.
48. Paull TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10: 886-95.
49. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003;5: 675-9.
50. Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. Science 2002;296:922-7.
51. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905-16.
52. Jeggo PA. DNA breakage and repair. Adv Genet 1998;38:185-218.
53. Couedel C, Mills KD, Barchi M, et al. Collaboration of homologous recombination and nonhomologous end-joining factors for the survival and integrity of mice and cells. Genes Dev 2004;18:1293-304.
54. Riballo E, Kuhne M, Rief N, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to γ-H2AX foci. Mol Cell 2004;16:715-24.
55. Muller-Tidow C, Ji P, Diederichs S, et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 2004;24:8917-28.
56. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
57. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005.
58. Hoss JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122: 598-609.
59. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003;1603:99-111.